Xuefeng Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xuefeng Li has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
Mengru Zhou
School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China
4 shared publicationsYanbin Shi
School of Pharmacy, Lanzhou University, Lanzhou 730000, China
4 shared publicationsJiaying Zhang
Lanzhou Univ, Inst Integrated Chinese & Western Med, Sch Basic Med Sci, Lanzhou 730000, Peoples R China
3 shared publicationsXiangxiang Wei
Lanzhou Univ, Inst Integrated Chinese & Western Med, Sch Basic Med Sci, Lanzhou 730000, Peoples R China
3 shared publicationsYang Yuan
Lanzhou Univ, Inst Integrated Chinese & Western Med, Sch Basic Med Sci, Lanzhou 730000, Peoples R China
3 shared publicationsYinghuan Dou
Lanzhou Univ, Inst Integrated Chinese & Western Med, Sch Basic Med Sci, Lanzhou 730000, Peoples R China
3 shared publications
Latest Publications
- Open Access
- 29 May 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (6) , 856
Bioactive Constituents, Mechanisms, and Complementary Therapeutic Applications of Food–Medicine Continuum Materia Medica for Atherosclerosis Prevention and Treatment
Cardiovascular disease (CVD) represents the leading cause of mortality worldwide, with atherosclerosis (AS) serving as its primary pathological foundation, involving multiple pathological processes, including lipid metabolism disorders, chronic inflammation, and endothelial dysfunction. The food and medicine continuum (FMC) concept originates from traditional Chinese medicine, emphasizing that certain foods possess both nutritional and medicinal value, aligning closely with the modern “food is medicine” philosophy. This narrative review examines the bioactive components and anti-atherosclerotic mechanisms of ten FMC materia medica: hawthorn fruit (Crataegus Fructus), ginkgo seed (Ginkgo Semen), milkvetch root (Astragali Radix), turmeric (Curcumae longae Rhizoma), ginger (Zingiberis Rhizoma Recens), glossy ganoderma (Ganoderma), Angelica sinensis (Angelicae sinensis Radix), barbary wolfberry fruit (Lycii Fructus), lotus leaf (Nelumbinis Folium), and honey (Mel). These materia medica are rich in bioactive constituents, including flavonoids, terpenoids, and polysaccharides, which can exert cardiovascular protective effects, such as regulating lipid metabolism, inhibiting inflammation and oxidative stress, improving endothelial function, and modulating gut microbiota. Regarding clinical evidence, meta-analyses support the beneficial effects of ginger and honey on cardiometabolic risk factors, though the field still faces challenges, including the need for higher-level clinical evidence and difficulties in product standardization. This review aims to integrate traditional knowledge with modern scientific approaches, providing scientific evidence for the development of functional foods and phytotherapy.
- 29 May 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (6) , 856
Open AccessBioactive Constituents, Mechanisms, and Complementary Therapeutic Applications of Food–Medicine Continuum Materia Medica for Atherosclerosis Prevention and Treatment
Cardiovascular disease (CVD) represents the leading cause of mortality worldwide, with atherosclerosis (AS) serving as its primary pathological foundation, involving multiple pathological processes, including lipid metabolism disorders, chronic inflammation, and endothelial dysfunction. The food and medicine continuum (FMC) concept originates from traditional Chinese medicine, emphasizing that certain foods possess both nutritional and medicinal value, aligning closely with the modern “food is medicine” philosophy. This narrative review examines the bioactive components and anti-atherosclerotic mechanisms of ten FMC materia medica: hawthorn fruit (Crataegus Fructus), ginkgo seed (Ginkgo Semen), milkvetch root (Astragali Radix), turmeric (Curcumae longae Rhizoma), ginger (Zingiberis Rhizoma Recens), glossy ganoderma (Ganoderma), Angelica sinensis (Angelicae sinensis Radix), barbary wolfberry fruit (Lycii Fructus), lotus leaf (Nelumbinis Folium), and honey (Mel). These materia medica are rich in bioactive constituents, including flavonoids, terpenoids, and polysaccharides, which can exert cardiovascular protective effects, such as regulating lipid metabolism, inhibiting inflammation and oxidative stress, improving endothelial function, and modulating gut microbiota. Regarding clinical evidence, meta-analyses support the beneficial effects of ginger and honey on cardiometabolic risk factors, though the field still faces challenges, including the need for higher-level clinical evidence and difficulties in product standardization. This review aims to integrate traditional knowledge with modern scientific approaches, providing scientific evidence for the development of functional foods and phytotherapy.
- Open Access
- 10 May 2026
- Published by Elsevier in Integrative Medicine Research
- Vol. 15 (3) , 101351
Design and methodology of the AI-empowered Clinical Evidence for Integrated Chinese-Western Medicine (ACE-iMed) platform
- 10 May 2026
- Published by Elsevier in Integrative Medicine Research
- Vol. 15 (3) , 101351
Open AccessDesign and methodology of the AI-empowered Clinical Evidence for Integrated Chinese-Western Medicine (ACE-iMed) platform
- Open Access
- 22 April 2026
- Published by MDPI AG in Preprints.org
Bioactive Constituents, Mechanisms, and Therapeutic Applications of Food-Medicine Continuum Herbs for Atherosclerosis Prevention and Treatment
Cardiovascular disease (CVD) represents the leading cause of mortality worldwide, with atherosclerosis (AS) serving as its primary pathological foundation, involving multiple pathological processes, including lipid metabolism disorders, chronic inflammation, and endothelial dysfunction. The food and medicine continuum (FMC) concept originates from traditional Chinese medicine, emphasizing that certain foods possess both nutritional and medicinal value, aligning closely with the modern "food is medicine" philosophy. This review systematically examines the bioactive components and anti-atherosclerotic mechanisms of ten FMC herbs: Hawthorn Fruit (Crataegus Fructus), Ginkgo Seed (Ginkgo Semen), Milkvetch Root (Astragali Radix), Turmeric (Curcumae Longae Rhizoma), Ginger (Zingiberis Rhizoma Recens ), Glossy Ganoderma (Ganoderma), Angelica sinensis(Angelicae Sinensis Radix), Barbary Wolfberry Fruit (Lycii Fructus), lotus leaf (Nelumbinis Folium), and Honey (Mel). These herbs are rich in bioactive constituents, including flavonoids, terpenoids, and polysaccharides, which can exert cardiovascular protective effects, such as regulating lipid metabolism, inhibiting inflammation and oxidative stress, improving endothelial function, and modulating gut microbiota. Regarding clinical evidence, meta-analyses support the beneficial effects of ginger and honey on cardiometabolic risk factors, though the field still faces challenges including the need for higher-level clinical evidence and difficulties in product standardization. This review aims to integrate traditional knowledge with modern scientific approaches, providing scientific evidence for the development of functional foods and phytotherapy.
- 22 April 2026
- Published by MDPI AG in Preprints.org
Open AccessBioactive Constituents, Mechanisms, and Therapeutic Applications of Food-Medicine Continuum Herbs for Atherosclerosis Prevention and Treatment
Cardiovascular disease (CVD) represents the leading cause of mortality worldwide, with atherosclerosis (AS) serving as its primary pathological foundation, involving multiple pathological processes, including lipid metabolism disorders, chronic inflammation, and endothelial dysfunction. The food and medicine continuum (FMC) concept originates from traditional Chinese medicine, emphasizing that certain foods possess both nutritional and medicinal value, aligning closely with the modern "food is medicine" philosophy. This review systematically examines the bioactive components and anti-atherosclerotic mechanisms of ten FMC herbs: Hawthorn Fruit (Crataegus Fructus), Ginkgo Seed (Ginkgo Semen), Milkvetch Root (Astragali Radix), Turmeric (Curcumae Longae Rhizoma), Ginger (Zingiberis Rhizoma Recens ), Glossy Ganoderma (Ganoderma), Angelica sinensis(Angelicae Sinensis Radix), Barbary Wolfberry Fruit (Lycii Fructus), lotus leaf (Nelumbinis Folium), and Honey (Mel). These herbs are rich in bioactive constituents, including flavonoids, terpenoids, and polysaccharides, which can exert cardiovascular protective effects, such as regulating lipid metabolism, inhibiting inflammation and oxidative stress, improving endothelial function, and modulating gut microbiota. Regarding clinical evidence, meta-analyses support the beneficial effects of ginger and honey on cardiometabolic risk factors, though the field still faces challenges including the need for higher-level clinical evidence and difficulties in product standardization. This review aims to integrate traditional knowledge with modern scientific approaches, providing scientific evidence for the development of functional foods and phytotherapy.
- 30 October 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 319, 117336
Stool-softening effect and action mechanism of free anthraquinones extracted from Rheum palmatum L. on water deficit-induced constipation in rats
- 30 October 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 319, 117336
Stool-softening effect and action mechanism of free anthraquinones extracted from Rheum palmatum L. on water deficit-induced constipation in rats
- Open Access
- 10 June 2023
- Published by Elsevier in Chinese Herbal Medicines
- Vol. 15 (3) , 391-397
Research and application of leek roots in medicinal field
- 10 June 2023
- Published by Elsevier in Chinese Herbal Medicines
- Vol. 15 (3) , 391-397
Open AccessResearch and application of leek roots in medicinal field
- 1 October 2022
- Vol. 42 (5) , 764-772
Shunxin decoction improves diastolic function in rats with heart failure with preserved ejection fraction induced by abdominal aorta constriction through cyclic guanosine monophosphate-dependent protein kinase Signaling Pathway
OBJECTIVE: To determine whether Shunxin decoction improves diastolic function in rats with heart failure with preserved ejection fraction (HFpEF) by regulating the cyclic guanosine monophosphatedependent protein kinase (cGMP-PKG) signaling pathway. METHODS: Except for control group 8 and sham surgery group 8, the remaining 32 male Sprague-Dawlay rats were developed into HFpEF rat models using the abdominal aorta constriction method. These rats in the HFpEF model were randomly divided into the model group, the Shunxin high-dose group, the Shunxin lowdose group, and the Qiliqiangxin capsule group. The three groups received high-dose Shunxin decoction, lowdose Shunxin decoction, and Qiliqiangxin capsule by gavage, respectively, for 14 d. After the intervention, the diastolic function of each rat was evaluated by testing E/A, heart index, hematoxylin- eosin staining, Masson, myocardial ultrastructure, and N-terminal pro-brain natriuretic peptide (NT-proBNP). The Bioinformatics Analysis Tool for Molecular Mechanism of Traditional Chinese Medicine (BATMAN-TCM) software was used to predict targets for which Shunxin decoction acts on the cGMP-PKG pathway. Natriuretic peptide receptor A (NPRA) and guanylate cyclase (GC) were detected by immunohistochemistry, and eNOS, phosphodiesterase 5A (PDE5A), and cGMP- dependent protein kinase 1(PKG I) were determined by Western blotting. RESULTS: Compared to the model group, the thickness of the interventricular septum at the end of diastole (IVSd) and the thickness of the posterior wall at the end of diastole (PWd) of the Shunxin decoction high-dose group, Shunxin decoction low-dose group, and Qiliqiangxin capsule group were all significantly reduced (P < 0.01). Furthermore, Shunxin decoction high-dose group E/A value was decreased (P < 0.01). Compared to the model group, the expression of NPRA and GC increased in the Shunxin decoction low-dose group and the Qiliqiangxin capsule group (P < 0.01). Compared to the model group, the expressions of eNOS and PKG I increased (P < 0.05) in the Shunxin decoction high-dose group. The expression of PDE5A expression decreased in the myocardium of the Shunxin decoction high-dose group, Shunxin decoction low-dose group, and Qiliqiangxin capsule group compared to the model group (P < 0.01). CONCLUSIONS: Shunxin decoction can improve diastolic function in rats with HFpEF. It increases the expression of NPRA, GC, and eNOS in the myocardial cell cGMP-PKG signaling pathway, upregulates cGMP expression, decreases PDE5A expression to reduce the cGMP degradation. Thus, the cGMP continually stimulates PKG I, reversing myocardial hypertrophy and improving myocardial compliance in HFpEF rats. (C) 2022 JTCM. All rights reserved.
- 1 October 2022
- Vol. 42 (5) , 764-772
Shunxin decoction improves diastolic function in rats with heart failure with preserved ejection fraction induced by abdominal aorta constriction through cyclic guanosine monophosphate-dependent protein kinase Signaling Pathway
OBJECTIVE: To determine whether Shunxin decoction improves diastolic function in rats with heart failure with preserved ejection fraction (HFpEF) by regulating the cyclic guanosine monophosphatedependent protein kinase (cGMP-PKG) signaling pathway. METHODS: Except for control group 8 and sham surgery group 8, the remaining 32 male Sprague-Dawlay rats were developed into HFpEF rat models using the abdominal aorta constriction method. These rats in the HFpEF model were randomly divided into the model group, the Shunxin high-dose group, the Shunxin lowdose group, and the Qiliqiangxin capsule group. The three groups received high-dose Shunxin decoction, lowdose Shunxin decoction, and Qiliqiangxin capsule by gavage, respectively, for 14 d. After the intervention, the diastolic function of each rat was evaluated by testing E/A, heart index, hematoxylin- eosin staining, Masson, myocardial ultrastructure, and N-terminal pro-brain natriuretic peptide (NT-proBNP). The Bioinformatics Analysis Tool for Molecular Mechanism of Traditional Chinese Medicine (BATMAN-TCM) software was used to predict targets for which Shunxin decoction acts on the cGMP-PKG pathway. Natriuretic peptide receptor A (NPRA) and guanylate cyclase (GC) were detected by immunohistochemistry, and eNOS, phosphodiesterase 5A (PDE5A), and cGMP- dependent protein kinase 1(PKG I) were determined by Western blotting. RESULTS: Compared to the model group, the thickness of the interventricular septum at the end of diastole (IVSd) and the thickness of the posterior wall at the end of diastole (PWd) of the Shunxin decoction high-dose group, Shunxin decoction low-dose group, and Qiliqiangxin capsule group were all significantly reduced (P < 0.01). Furthermore, Shunxin decoction high-dose group E/A value was decreased (P < 0.01). Compared to the model group, the expression of NPRA and GC increased in the Shunxin decoction low-dose group and the Qiliqiangxin capsule group (P < 0.01). Compared to the model group, the expressions of eNOS and PKG I increased (P < 0.05) in the Shunxin decoction high-dose group. The expression of PDE5A expression decreased in the myocardium of the Shunxin decoction high-dose group, Shunxin decoction low-dose group, and Qiliqiangxin capsule group compared to the model group (P < 0.01). CONCLUSIONS: Shunxin decoction can improve diastolic function in rats with HFpEF. It increases the expression of NPRA, GC, and eNOS in the myocardial cell cGMP-PKG signaling pathway, upregulates cGMP expression, decreases PDE5A expression to reduce the cGMP degradation. Thus, the cGMP continually stimulates PKG I, reversing myocardial hypertrophy and improving myocardial compliance in HFpEF rats. (C) 2022 JTCM. All rights reserved.
- 9 March 2022
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 292, 115179
Identification and action mechanism of lipid regulating components from Rhei Radix et rhizoma
- 9 March 2022
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 292, 115179
Identification and action mechanism of lipid regulating components from Rhei Radix et rhizoma
- Open Access
Production of SARS-CoV-2 Virus-Like Particles in Insect Cells
Coronavirus disease (COVID-19) causes a serious threat to human health. Virus-like particles (VLPs) constitute a promising platform in SARS-CoV-2 vaccine development. In this study, the E, M, and S genes were cloned into multiple cloning sites of a new triple expression plasmid with one p10 promoter, two pPH promoters, and three multiple cloning sites. The plasmid was transformed into DH10 BacTMEscherichia coli competent cells to obtain recombinant bacmid. Then the recombinant bacmid was transfected in ExpiSf9TM insect cells to generate recombinant baculovirus. After ExpiSf9TM cells infection with the recombinant baculovirus, the E, M, and S proteins were expressed in insect cells. Finally, SARS-CoV-2 VLPs were self-assembled in insect cells after infection. The morphology and the size of SARS-CoV-2 VLPs are similar to the native virions.
Open AccessProduction of SARS-CoV-2 Virus-Like Particles in Insect Cells
Coronavirus disease (COVID-19) causes a serious threat to human health. Virus-like particles (VLPs) constitute a promising platform in SARS-CoV-2 vaccine development. In this study, the E, M, and S genes were cloned into multiple cloning sites of a new triple expression plasmid with one p10 promoter, two pPH promoters, and three multiple cloning sites. The plasmid was transformed into DH10 BacTMEscherichia coli competent cells to obtain recombinant bacmid. Then the recombinant bacmid was transfected in ExpiSf9TM insect cells to generate recombinant baculovirus. After ExpiSf9TM cells infection with the recombinant baculovirus, the E, M, and S proteins were expressed in insect cells. Finally, SARS-CoV-2 VLPs were self-assembled in insect cells after infection. The morphology and the size of SARS-CoV-2 VLPs are similar to the native virions.
- Open Access
- 1 June 2020
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 20 (1) , 1-13
The protective effects of angelica organic acid against ox-LDL-induced autophagy dysfunction of HUVECs
Background: Angelica root is the dry root of the Umbelliferae plantAngelica sinensis (oliv) Diels. Angelica organic acid (OA) is the main active ingredient in Angelica sinensis, and it exerts potential anti-atherosclerotic effects by preventing Oxidized low-density lipoprotein (Ox-LDL) induced endothelial injury. To study the protective effects of OA on ox-LDL-induced HUVECs autophagic flux dysfunction and inflammatory injury.Methods: OA were isolated by water extraction and alcohol precipitation, and then the content of ferulic acid (FA) in the OA was determined by high performance liquid chromatography. The ox-LDL-induced endothelial injury model was established. The effect of ferulic acid on the survival of Human umbilical vein endothelial cells (HVUECs) was detected by CCK-8 assay. HUVECs were pretreated with different concentrations of OA (20 μmol/L, 40 μmol/L, and 80 μmol/L), and Western Blot was used to detect the expressions of LC3II, p62, MCP-1, VCAM-1 and LOX-1. The autophagosomes in HUVECs were observed by transmission electron microscopy (TEM).Results: 20 μmol/L OA could increase the expression of LC3II and decrease the expression of p62, MCP-1, VCAM-1 and LOX-1. The results of TEM showed that angelica organic acids promoted cell organelle degradation in autolysosomes.Conclusion: OA could reduce inflammation, protect endothelial cells and play an anti-atherosclerotic role by enhancing the autophagy flux of damaged endothelial cells, in which FA the major active ingredient of OA played a major role.
- 1 June 2020
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 20 (1) , 1-13
Open AccessThe protective effects of angelica organic acid against ox-LDL-induced autophagy dysfunction of HUVECs
Background: Angelica root is the dry root of the Umbelliferae plantAngelica sinensis (oliv) Diels. Angelica organic acid (OA) is the main active ingredient in Angelica sinensis, and it exerts potential anti-atherosclerotic effects by preventing Oxidized low-density lipoprotein (Ox-LDL) induced endothelial injury. To study the protective effects of OA on ox-LDL-induced HUVECs autophagic flux dysfunction and inflammatory injury.Methods: OA were isolated by water extraction and alcohol precipitation, and then the content of ferulic acid (FA) in the OA was determined by high performance liquid chromatography. The ox-LDL-induced endothelial injury model was established. The effect of ferulic acid on the survival of Human umbilical vein endothelial cells (HVUECs) was detected by CCK-8 assay. HUVECs were pretreated with different concentrations of OA (20 μmol/L, 40 μmol/L, and 80 μmol/L), and Western Blot was used to detect the expressions of LC3II, p62, MCP-1, VCAM-1 and LOX-1. The autophagosomes in HUVECs were observed by transmission electron microscopy (TEM).Results: 20 μmol/L OA could increase the expression of LC3II and decrease the expression of p62, MCP-1, VCAM-1 and LOX-1. The results of TEM showed that angelica organic acids promoted cell organelle degradation in autolysosomes.Conclusion: OA could reduce inflammation, protect endothelial cells and play an anti-atherosclerotic role by enhancing the autophagy flux of damaged endothelial cells, in which FA the major active ingredient of OA played a major role.
- Open Access
- 23 September 2019
- Published by Springer Nature in Chinese Medicine
- Vol. 14 (1) , 1-10
Preparation, optimization and in vitro–in vivo evaluation of Shunxin sustained release granules
Background: Shunxinzufang decoction is tutors, empirical formula and has been used in Chinese patients of HFpEF for several years. The aim of this study was to make into sustained release granules and select the best formula for the preparation of Shunxin sustained release granules and to evaluate its in vivo and in vitro drug release behavior. Methods: Response surface methodology and Center composite design were applied to screen the optimal formula of Shunxin sustained release granules. HPLC was used to detect indicative ingredients—paeoniflorin, calycosin-7-glucoside and ferulic acid in Shunxin sustained release granules. The in vitro sustained release character of indicative ingredients was investigated in simulated digestive fluids. In-vivo process of active components was studied through pharmacokinetics. Results: The optimal formula of Shunxin sustained release granules consisted of 35% shunxinzufang extract and 65% HPMC/starch (HPMC/starch ratio = 2:1). Three indicative components can be separated well under selected HPLC conditions. Compared with Shunxinzufang extract, the active components of Shunxin sustained release granules have obvious sustained-release character and improved bioavailability. Conclusion: Shunxin sustained release granules has obvious sustained-release character and improved bioavailability.
- 23 September 2019
- Published by Springer Nature in Chinese Medicine
- Vol. 14 (1) , 1-10
Open AccessPreparation, optimization and in vitro–in vivo evaluation of Shunxin sustained release granules
Background: Shunxinzufang decoction is tutors, empirical formula and has been used in Chinese patients of HFpEF for several years. The aim of this study was to make into sustained release granules and select the best formula for the preparation of Shunxin sustained release granules and to evaluate its in vivo and in vitro drug release behavior. Methods: Response surface methodology and Center composite design were applied to screen the optimal formula of Shunxin sustained release granules. HPLC was used to detect indicative ingredients—paeoniflorin, calycosin-7-glucoside and ferulic acid in Shunxin sustained release granules. The in vitro sustained release character of indicative ingredients was investigated in simulated digestive fluids. In-vivo process of active components was studied through pharmacokinetics. Results: The optimal formula of Shunxin sustained release granules consisted of 35% shunxinzufang extract and 65% HPMC/starch (HPMC/starch ratio = 2:1). Three indicative components can be separated well under selected HPLC conditions. Compared with Shunxinzufang extract, the active components of Shunxin sustained release granules have obvious sustained-release character and improved bioavailability. Conclusion: Shunxin sustained release granules has obvious sustained-release character and improved bioavailability.